Auf dieser Seite
CUE Cue Biopharma, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 14, 2026
$25,57
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$0,1752-Wochen-Tief
$45,5052-Wochen-Hoch
Marktkapitalisierung (MRQ)
$134M
P/E (TTM)
-1.0
EPS (TTM)
$-25.24
Umsatz (TTM)
$38M
Ihre Abzeichen
52W-Spanne
$0–$46
Analystenbewertung
BUY
Kursziel
$88
P/E
-1.0
ROE
-1603.5%
Nettogewinnmarge
-435.8%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
CUE Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$25.57
Marktkapitalisierung (MRQ)
$134M
P/E (TTM)
-1.0
EPS (TTM)
$-25.24
Umsatz (TTM)
$38M
ROE (TTM)
-1603.5%
52W-Spanne
$0–$46
CUE Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 24. April 2026 | 1-for-30 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$27M2018-12-31 → 2025-12-31
EPS$-0.282021-12-31 → 2025-12-31
Freier Cashflow$-22M2020-12-31 → 2025-12-31
Nettogewinnmarge-435.8%2020-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | CUE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -1.05-Jahres-Durchschnitt ≈-3.0 | ≈-3.0 | · | · | |
| P/S (TTM) | 3.65-Jahres-Durchschnitt ≈30.4 | ≈30.4 | 4.6 | Fairer Wert | |
| K/B (MRQ) | 57.95-Jahres-Durchschnitt ≈3.1 | ≈3.1 | 2.8 | Überbewertet | |
| Kurs / FCF (TTM) | -2.75-Jahres-Durchschnitt ≈-3.6 | ≈-3.6 | · | · | |
| Kurs / Cashflow (TTM) | -2.75-Jahres-Durchschnitt ≈-3.7 | ≈-3.7 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 3.15-Jahres-Durchschnitt ≈3.1 | ≈3.1 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | CUE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -262.0%5-Jahres-Durchschnitt ≈-1212.1% | ≈-1212.1% | -226.0% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -96.7%5-Jahres-Durchschnitt ≈-1212.1% | ≈-1212.1% | -226.0% | Schwach | |
| Nettogewinnmarge (TTM) | -435.8%5-Jahres-Durchschnitt ≈-1202.3% | ≈-1202.3% | -220.0% | Schwach | |
| ROA (TTM) | -459.6%5-Jahres-Durchschnitt ≈-66.7% | ≈-66.7% | -30.4% | Schwach | |
| ROE (TTM) | -1603.5%5-Jahres-Durchschnitt ≈-119.2% | ≈-119.2% | -58.5% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | CUE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 1.35-Jahres-Durchschnitt ≈3.9 | ≈3.9 | 7.9 | Geringe Liquidität | |
| Quick Ratio | 2.45-Jahres-Durchschnitt ≈3.4 | ≈3.4 | 7.5 | Geringe Liquidität | |
| Interest Coverage (Zinsdeckungsgrad) | -265.55-Jahres-Durchschnitt ≈-360.6 | ≈-360.6 | -20.1 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | CUE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 195.8%5-Jahres-Durchschnitt ≈177.6% | ≈177.6% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 180.5%5-Jahres-Durchschnitt ≈62.0% | ≈62.0% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 54.2% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | CUE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.75-Jahres-Durchschnitt ≈0.2 | ≈0.2 | 0.1 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 8.55-Jahres-Durchschnitt ≈5.8 | ≈5.8 | 6.0 | Spitzenklasse | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$947.1K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-248.9%
Nächster Bericht
Nov 10, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 14, 2026 | $-24.14 | $-1.71 | -1314.3% |
| 30. September 2025 | $-2.10 | $-2.83 | 25.7% | |
| 30. Juni 2025 | $-2.70 | $-4.24 | 36.4% | |
| 31. März 2025 | $-5.10 | $-4.65 | -9.8% | |
| 31. Dezember 2024 | $-3.90 | $-4.73 | 17.5% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27M | $9M | $5M | $1M | $15M | $3M | $3M | $1M | |
| R&D Expense | $38M | $36M | $41M | $39M | $41M | $34M | $27M | $29M | |
| SG&A Expense | $16M | $15M | $17M | $16M | $17M | $15M | $13M | $11M | |
| Operating Expenses | $54M | $51M | $58M | $54M | $59M | $48M | $40M | $40M | |
| Operating Income | $-27M | $-42M | $-52M | $-53M | $-44M | $-45M | $-37M | $-39M | |
| Interest Expense | $100.0K | $100.0K | $100.0K | $109.0K | · | · | · | · | |
| Other Non-op | $450.0K | $826.0K | $1M | $215.0K | $45.9K | $463.9K | $482.8K | $165.3K | |
| Pretax Income | · | · | · | $-53M | $-44M | $-45M | $-36M | $-38M | |
| Income Tax | $500.0K | $0 | · | $0 | $495.0K | $206.2K | $412.5K | $825.0K | |
| Net Income | $-27M | $-41M | $-51M | $-53M | $-44M | $-45M | $-37M | $-39M | |
| EPS (Basic) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | · | · | · | |
| EPS (Diluted) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | · | · | · | |
| Shares (Basic) | 94,731,768 | 56,328,348 | 45,754,794 | 35,649,134 | 31,285,418 | · | · | · | |
| Shares (Diluted) | 94,731,768 | 56,328,348 | 45,754,794 | 35,649,134 | 31,285,418 | · | · | · | |
| EBITDA | $-27M | $-42M | $-52M | $-53M | $-44M | $-45M | · | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27M | $22M | $49M | $52M | $64M | $75M | $44M | $21M | |
| Receivables | $6M | $945.0K | $2M | $57.0K | $3M | $1M | $754.9K | · | |
| Prepaid Expense | $1M | $805.0K | $955.0K | $841.0K | $954.8K | $1M | $860.1K | $1M | |
| Current Assets | $37M | $25M | $51M | $77M | $68M | $88M | $61M | $41M | |
| PP&E (Net) | $241.0K | $471.0K | $795.0K | $1M | $2M | $2M | $2M | $3M | |
| PP&E (Gross) | $4M | $4M | $4M | $6M | $6M | $5M | $4M | $4M | |
| Accum. Depreciation | $4M | $4M | $4M | $4M | $3M | $3M | $2M | $1M | |
| Other Non-current Assets | $94.0K | $105.0K | $117.0K | $128.0K | $140.0K | $401.7K | $673.6K | $808.7K | |
| Total Assets | $42M | $32M | $62M | $91M | $83M | $100M | $72M | $45M | |
| Accounts Payable | $4M | $3M | $4M | $3M | $3M | $2M | $882.7K | $2M | |
| Accrued Liabilities | $2M | $3M | $4M | $4M | $5M | $3M | $2M | $2M | |
| Short-term Debt | · | $37.0K | $37.0K | $74.0K | · | · | · | · | |
| Current Liabilities | $13M | $14M | $17M | $12M | $13M | $16M | $12M | $6M | |
| Capital Leases | $2M | $1M | $3M | $6M | $5M | $2M | $1M | · | |
| Total Liabilities | $16M | $15M | $24M | $26M | $18M | $21M | $17M | $11M | |
| Long-term Debt | · | · | $4M | $8M | · | · | · | · | |
| Total Debt | · | $37.0K | $8M | $10M | · | · | · | · | |
| Common Stock | $3.0K | $62.0K | $47.0K | $43.0K | $32.2K | $30.4K | $26.6K | $20.7K | |
| Retained Earnings | $-368M | $-342M | $-301M | $-250M | $-197M | $-153M | $-109M | $-72M | |
| AOCI | · | $0 | $0 | $-96.0K | $0 | $7.1K | $-10.3K | $-11.0K | |
| Stockholders' Equity | $26M | $17M | $37M | $66M | $65M | $79M | $55M | $34M | |
| Liabilities + Equity | $42M | $32M | $62M | $91M | $83M | $100M | $72M | $45M | |
| Shares Outstanding | 3,220,707 | 61,819,101 | 47,215,116 | 47,215,116 | 32,202,496 | 30,351,366 | 26,562,178 | 20,697,453 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $958.0K | $397.0K | $556.0K | $922.0K | $1M | $1M | $810.8K | $760.0K | |
| Stock-based Comp | $5M | $7M | $8M | $9M | $12M | $10M | $7M | $7M | |
| Amort. of Intangibles | · | · | · | · | · | $11.7K | $11.7K | · | |
| Operating Cash Flow | $-22M | $-36M | $-40M | $-42M | $-39M | $-32M | $-31M | $-26M | |
| CapEx | $177.0K | $66.0K | $0 | $171.0K | $913.0K | $595.3K | $46.4K | $2M | |
| Investing Cash Flow | $75.0K | $32.0K | $25M | $-25M | $9M | $4M | $3M | $-20M | |
| Stock Issued | $28M | $11M | $0 | $23M | $0 | $57M | $49M | · | |
| Stock Repurchased | · | · | $0 | $200.0K | $750.1K | $271.1K | $91.0K | · | |
| Net Stock Activity | $28M | $11M | $0 | $23M | $17M | $56M | · | · | |
| Financing Cash Flow | $26M | $10M | $12M | $54M | $19M | $59M | $51M | $4M | |
| Net Change in Cash | $5M | $-26M | $-3M | $-13M | $-10M | $31M | $23M | $-43M | |
| Taxes Paid | $500.0K | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-22M | $-36M | $-40M | $-42M | $-40M | $-33M | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -96.7% | -446.9% | -949.9% | -4274.3% | -292.6% | -1428.0% | · | · | |
| Net Margin | -96.9% | -438.0% | -924.1% | -4257.1% | -295.6% | -1419.8% | · | · | |
| Pretax Margin | · | · | · | -4257.1% | -292.2% | -1413.3% | · | · | |
| EBITDA Margin | -96.7% | -446.9% | -949.9% | -4274.3% | -292.6% | -1428.0% | · | · | |
| ROA | -71.5% | -86.8% | -66.4% | -60.7% | -48.3% | -52.3% | · | · | |
| ROE | -119.3% | -189.8% | -127.2% | -91.0% | -68.5% | -53.8% | · | · | |
| ROIC | · | · | · | -70.2% | -67.5% | -57.3% | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 1.8 | 3.0 | 6.7 | 5.4 | 5.4 | · | · | |
| Quick Ratio | 2.4 | 1.7 | 2.9 | 4.5 | 5.3 | 4.7 | · | · | |
| Debt / Equity | · | 0.0 | 0.2 | 0.2 | · | · | · | · | |
| LT Debt / Equity | · | 0.0 | 0.1 | 0.1 | · | · | · | · | |
| Interest Coverage | -265.5 | -415.0 | -401.1 | · | · | · | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.2 | 0.1 | 0.0 | 0.2 | 0.0 | · | · | |
| Receivables Turnover | 8.5 | 7.0 | 6.3 | 0.8 | 6.6 | 2.9 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.27 | $0.28 | $0.86 | $1.53 | $2.03 | $2.60 | · | · | |
| Revenue / Share | $0.29 | $0.16 | $0.12 | $0.03 | · | · | · | · | |
| Cash Flow / Share | $-0.23 | $-0.65 | $-0.87 | $-1.17 | · | · | · | · | |
| Cash / Share | $0.28 | $0.36 | $1.13 | $1.20 | $2.00 | $2.47 | · | · | |
| EPS (TTM) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 195.8% | 69.2% | 341.0% | -91.7% | 373.7% | · | · | · | |
| Revenue CAGR 3Y | 180.5% | -14.7% | 20.3% | · | · | · | · | · | |
| Revenue CAGR 5Y | 54.2% | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $27M | $9M | $5M | $1M | $15M | $3M | $3M | $1M | |
| Net Income TTM | $-27M | $-41M | $-51M | $-53M | $-44M | $-45M | $-37M | $-39M | |
| Market Cap | $29M | $67M | $114M | $123M | $364M | $380M | · | · | |
| Enterprise Value | · | $45M | $73M | $81M | · | · | · | · | |
| P/E | -1.1 | -1.5 | -2.4 | -1.9 | -8.0 | · | · | · | |
| P/S | 1.1 | 7.3 | 20.7 | 98.5 | 24.4 | 120.4 | · | · | |
| P/B | 1.1 | 3.9 | 3.1 | 1.9 | 5.6 | 4.8 | · | · | |
| P / Tangible Book | 1.1 | 3.9 | 3.1 | 1.9 | 5.6 | 4.8 | · | · | |
| P / Cash Flow | -1.4 | -1.9 | -2.8 | -2.9 | -9.4 | -11.7 | · | · | |
| P / FCF | -1.3 | -1.9 | -2.8 | -2.9 | -9.2 | -11.5 | · | · | |
| EV / EBITDA | · | -1.1 | -1.4 | -1.5 | · | · | · | · | |
| EV / FCF | · | -1.2 | -1.8 | -1.9 | · | · | · | · | |
| EV / Revenue | · | 4.8 | 13.4 | 65.2 | · | · | · | · | |
| Earnings Yield | -91.8% | -66.1% | -42.0% | -52.3% | -12.5% | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $6M | $22M | $2M | $3M | $421.0K | $2M | $3M | $3M | $2M | $2M | $2M | $1M | $187.0K | $151.0K | $68.0K | |
| R&D Expense | $49M | $7M | $17M | $5M | $8M | $9M | $7M | $9M | $10M | $10M | $11M | $10M | $11M | $9M | $11M | $8M | |
| SG&A Expense | $47M | $4M | $3M | $5M | $4M | $4M | $4M | $3M | $4M | $4M | $5M | $4M | $4M | $4M | $4M | $4M | |
| Operating Expenses | $96M | $11M | $20M | $10M | $12M | $13M | $11M | $12M | $13M | $14M | $16M | $14M | $15M | $14M | $15M | $11M | |
| Operating Income | $-88M | $-5M | $2M | $-8M | $-9M | $-12M | $-10M | $-9M | $-10M | $-13M | $-14M | $-11M | $-14M | $-13M | $-15M | $-11M | |
| Interest Expense | · | · | · | · | $33.0K | $100.0K | · | · | · | $33.0K | $-537.0K | $254.0K | $350.0K | $33.0K | $18.0K | $33.0K | |
| Other Non-op | $-65M | $175.0K | $108.0K | $147.0K | $153.0K | $42.0K | $138.0K | $155.0K | $212.0K | $321.0K | $399.0K | $414.0K | $332.0K | $271.0K | $274.0K | $76.0K | |
| Net Income | $-153M | $-5M | $2M | $-7M | $-8M | $-12M | $-9M | $-9M | $-10M | $-12M | $-13M | $-11M | $-13M | $-13M | $-15M | $-11M | |
| EPS (Basic) | $-24.14 | $-1.08 | $0.05 | $-0.07 | $-2.67 | $-4.95 | $-0.10 | $-0.17 | $-0.20 | $-0.25 | $-0.29 | $-0.24 | $-0.29 | $-0.29 | $-0.37 | $-0.31 | |
| EPS (Diluted) | $-24.14 | $-1.08 | $0.05 | $-0.07 | $-2.67 | $-4.95 | $-0.10 | $-0.17 | $-0.20 | $-0.25 | $-0.29 | $-0.24 | $-0.29 | $-0.29 | $-0.37 | $-0.31 | |
| Shares (Basic) | 6,340,844 | 4,807,494 | · | 100,869,349 | 3,181,980 | 2,475,156 | · | 51,229,701 | 50,174,756 | 49,466,711 | · | 46,358,555 | 44,798,760 | 44,652,353 | · | 35,383,430 | |
| Shares (Diluted) | 6,340,844 | 4,807,494 | · | 100,869,349 | 3,181,980 | 2,475,156 | · | 51,229,701 | 50,174,756 | 49,466,711 | · | 46,358,555 | 44,798,760 | 44,652,353 | · | 35,383,430 | |
| EBITDA | $-88M | $-5M | · | $-8M | $-9M | $-12M | · | $-9M | $-10M | $-13M | · | $-11M | $-14M | $-13M | · | $-11M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17M | $16M | $27M | $12M | $27M | $13M | $22M | $32M | $30M | $41M | $49M | $55M | $53M | $56M | $52M | $30M | |
| Receivables | $5M | $5M | $6M | $387.0K | $532.0K | $0 | $945.0K | $3M | $2M | $1M | $2M | $2M | $1M | $196.0K | $57.0K | $796.0K | |
| Prepaid Expense | $2M | $2M | $1M | $3M | $2M | $2M | $805.0K | $2M | $2M | $2M | $955.0K | $1M | $2M | $2M | $841.0K | $2M | |
| Current Assets | $27M | $26M | $37M | $26M | $31M | $16M | $25M | $37M | $34M | $45M | $51M | $58M | $61M | $69M | $77M | $62M | |
| PP&E (Net) | $255.0K | $288.0K | $241.0K | $307.0K | $454.0K | $523.0K | $471.0K | $570.0K | $667.0K | $754.0K | $795.0K | $1M | $1M | $1M | $1M | $2M | |
| PP&E (Gross) | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $6M | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $4M | |
| Other Non-current Assets | $88.0K | $90.0K | $94.0K | $96.0K | $283.0K | $102.0K | $105.0K | $108.0K | $111.0K | $114.0K | $117.0K | $120.0K | $123.0K | $125.0K | $128.0K | $131.0K | |
| Total Assets | $31M | $31M | $42M | $32M | $41M | $22M | $32M | $45M | $42M | $54M | $62M | $69M | $73M | $82M | $91M | $76M | |
| Accounts Payable | $4M | $3M | $4M | $2M | $4M | $4M | $3M | $6M | $4M | $4M | $4M | $2M | $2M | $2M | $3M | $2M | |
| Accrued Liabilities | $15M | $1M | $2M | $2M | $2M | $4M | $3M | $3M | $5M | $5M | $4M | $5M | $4M | $3M | $4M | $4M | |
| Short-term Debt | · | · | · | · | · | $100.0K | · | · | · | $37.0K | · | · | · | · | · | $37.0K | |
| Current Liabilities | $21M | $7M | $13M | $16M | $19M | $15M | $14M | $17M | $16M | $18M | $17M | $17M | $16M | $14M | $12M | $10M | |
| Capital Leases | $1M | $2M | $2M | $3M | $3M | $176.0K | $1M | $1M | $2M | $3M | $3M | $4M | $5M | $5M | $6M | $6M | |
| Total Liabilities | $28M | $9M | $16M | $18M | $23M | $16M | $15M | $19M | $21M | $24M | $24M | $26M | $27M | $27M | $26M | $26M | |
| Long-term Debt | · | · | · | · | · | · | · | $1M | $2M | $3M | · | $5M | $6M | $7M | · | $9M | |
| Total Debt | · | · | · | · | · | $100.0K | · | $5M | $6M | $7M | · | $9M | $10M | $10M | · | $10M | |
| Common Stock | $5.0K | $3.0K | $97.0K | $78.0K | $76.0K | $62.0K | $62.0K | $60.0K | $48.0K | $48.0K | $47.0K | $45.0K | $44.0K | $43.0K | $43.0K | $35.0K | |
| Retained Earnings | $-527M | $-374M | $-368M | $-370M | $-363M | $-354M | $-342M | $-332M | $-324M | $-314M | $-301M | $-288M | $-277M | $-264M | $-250M | $-236M | |
| AOCI | · | · | · | $1.0K | · | · | · | · | · | · | · | $0 | $-5.0K | $-39.0K | $-96.0K | $-92.0K | |
| Stockholders' Equity | $2M | $22M | $26M | $13M | $18M | $7M | $17M | $25M | $22M | $30M | $37M | $43M | $46M | $55M | $66M | $51M | |
| Liabilities + Equity | $31M | $31M | $42M | $32M | $41M | $22M | $32M | $45M | $42M | $54M | $62M | $69M | $73M | $82M | $91M | $76M | |
| Shares Outstanding | 5,229,392 | 3,255,359 | 96,621,218 | 77,781,743 | 76,446,884 | 61,819,101 | 61,819,101 | 60,207,717 | 48,643,316 | 48,643,316 | 47,215,116 | 45,123,281 | 43,744,414 | 43,178,150 | 47,215,116 | 35,385,582 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $36.0K | $566.0K | $678.0K | $80.0K | $99.0K | $101.0K | $98.0K | $101.0K | $99.0K | $99.0K | $113.0K | $130.0K | $136.0K | $177.0K | $203.0K | $201.0K | |
| Stock-based Comp | $24M | $48.0K | $610.0K | $2M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-29M | $-11M | $-1M | $-9M | $-3M | $-8M | $-9M | $-8M | $-10M | $-10M | $-11M | $-8M | $-10M | $-11M | $-11M | $-7M | |
| CapEx | $0 | $121.0K | $0 | $0 | $27.0K | $150.0K | $2.0K | $-1.0K | $10.0K | $55.0K | $0 | $0 | $0 | $0 | $1.0K | $78.0K | |
| Investing Cash Flow | $0 | $-121.0K | $7M | $-7M | $-27.0K | $-150.0K | $-1.0K | $98.0K | $-10.0K | $-55.0K | $0 | $5M | $5M | $15M | $5M | $-30M | |
| Stock Issued | · | · | $10M | $0 | · | · | $-8.0K | $11M | · | · | · | · | · | · | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $9.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $30M | $306.0K | $9M | $1.0K | $18M | $-1M | $-932.0K | $10M | $-1M | $2M | $5M | $5M | $2M | $388.0K | $27M | $-9.0K | |
| Net Change in Cash | $1M | $-11M | $15M | $-16M | $14M | $-9M | $-10M | $2M | $-11M | $-7M | $-6M | $2M | $-3M | $5M | $22M | $-36M | |
| Free Cash Flow | · | $-11M | · | · | · | $-8M | · | · | · | $-10M | · | · | · | $-11M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1113.3% | -94.1% | · | -353.4% | -292.3% | -2921.4% | · | -264.2% | -390.6% | -737.8% | · | -543.8% | -978.1% | -7155.1% | · | -16222.1% | |
| Net Margin | -1943.2% | -91.1% | · | -346.6% | -287.1% | -2911.4% | · | -259.6% | -382.7% | -719.1% | · | -524.0% | -954.0% | -7010.2% | · | -16110.3% | |
| EBITDA Margin | -1113.3% | -94.1% | · | -353.4% | -292.3% | -2921.4% | · | -264.2% | -390.6% | -737.8% | · | -543.8% | -978.1% | -7155.1% | · | -16222.1% | |
| ROA | -428.7% | -19.5% | · | -19.5% | -20.4% | -32.2% | · | -15.2% | -17.6% | -18.2% | · | -15.2% | -16.7% | -15.2% | · | -14.1% | |
| ROE | -1495.6% | -36.7% | · | -38.6% | -42.6% | -67.0% | · | -25.5% | -30.1% | -29.0% | · | -23.6% | -24.9% | -21.9% | · | -19.2% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 3.6 | · | 1.7 | 1.6 | 1.0 | · | 2.2 | 2.1 | 2.5 | · | 3.3 | 3.7 | 5.0 | · | 6.0 | |
| Quick Ratio | 1.1 | 2.9 | · | 0.8 | 1.5 | 0.8 | · | 2.1 | 1.9 | 2.3 | · | 3.3 | 3.3 | 4.1 | · | 3.0 | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | 0.2 | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -383.9 | · | -45.0 | -38.6 | -40.5 | · | -89.0 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 2.7 | 2.1 | · | 1.2 | 2.5 | 0.6 | · | 1.4 | 1.8 | 2.2 | · | 1.7 | 1.5 | 0.3 | · | 0.1 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.44 | $6.64 | · | $0.17 | $0.24 | $0.11 | · | $0.42 | $0.44 | $0.62 | · | $0.95 | $1.05 | $1.27 | · | $1.43 | |
| Revenue / Share | $1.24 | $1.18 | · | $0.02 | $0.03 | $0.01 | · | $0.07 | $0.05 | $0.03 | · | $0.05 | $0.03 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-2.28 | · | · | · | $-0.11 | · | · | · | $-0.20 | · | · | · | $-0.24 | · | · | |
| Cash / Share | $3.33 | $5.03 | · | $0.15 | $0.36 | $0.21 | · | $0.54 | $0.62 | $0.84 | · | $1.21 | $1.21 | $1.30 | · | $0.84 | |
| EPS (TTM) | $-25.24 | $-3.77 | · | $-7.79 | $-7.89 | $-5.42 | · | $-0.91 | $-0.98 | $-1.07 | · | $-1.19 | $-1.26 | $-1.34 | · | $-1.37 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $38M | $33M | · | $7M | $8M | $8M | · | $10M | $8M | $7M | · | $4M | $2M | $432.0K | · | $9M | |
| Net Income TTM | $-164M | $-20M | · | $-38M | $-39M | $-41M | · | $-45M | $-47M | $-50M | · | $-52M | $-52M | $-52M | · | $-47M | |
| Market Cap | $165M | $748.7K | · | $56M | $52M | $56M | · | $46M | $60M | $92M | · | $104M | $160M | $154M | · | $79M | |
| Enterprise Value | · | · | · | · | · | $43M | · | $18M | $37M | $58M | · | $58M | $117M | $108M | · | $59M | |
| P/E | -1.3 | -0.1 | · | -0.1 | -0.1 | -0.2 | · | -0.8 | -1.3 | -1.8 | · | -1.9 | -2.9 | -2.7 | · | -1.6 | |
| P/S | 4.4 | 0.0 | · | 7.9 | 6.3 | 7.0 | · | 4.8 | 7.3 | 13.1 | · | 27.2 | 89.3 | 356.8 | · | 8.4 | |
| P/B | 71.4 | 0.0 | · | 4.2 | 2.9 | 8.6 | · | 1.8 | 2.8 | 3.1 | · | 2.4 | 3.5 | 2.8 | · | 1.6 | |
| P / Tangible Book | 71.4 | 0.0 | · | 4.2 | 2.9 | 8.6 | · | 1.8 | 2.8 | 3.1 | · | 2.4 | 3.5 | 2.8 | · | 1.6 | |
| P / Cash Flow | · | -0.1 | · | · | · | -6.9 | · | · | · | -9.4 | · | · | · | -14.2 | · | · | |
| EV / Revenue | · | · | · | · | · | 5.4 | · | 1.9 | 4.4 | 8.3 | · | 15.2 | 65.4 | 249.8 | · | 6.3 | |
| Earnings Yield | -80.0% | -1639.1% | · | -1083.5% | -1156.9% | -594.9% | · | -120.2% | -79.0% | -56.6% | · | -51.7% | -34.5% | -37.5% | · | -61.4% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $27M | $9M | $5M | $1M | $15M |
| Betriebsgewinnmarge % | -96.7% | -446.9% | -949.9% | -4274.3% | -292.6% |
| Nettoergebnis | $-27M | $-41M | $-51M | $-53M | $-44M |
| Verwässerte EPS | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | · | 0.0 | 0.2 | 0.2 | · |
| Liquiditätsgrad | 2.7 | 1.8 | 3.0 | 6.7 | 5.4 |
| Quick Ratio | 2.4 | 1.7 | 2.9 | 4.5 | 5.3 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-22M | $-36M | $-40M | $-42M | $-40M |
Institutionelle Eigentümer (13F) 3 Einreicher · $921K gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
3
Gehaltener Wert
$921K
Neue Positionen
0
Geschlossene Positionen
54
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 0 | 54 | 0 | 0 | · |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen. Änderung gegenüber Vorquartal nicht angezeigt: Die Einreicherabdeckung unterscheidet sich zwischen diesen beiden Quartalen zu stark für einen zuverlässigen Vergleich.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $919.280 | 3.014.034 | 99,80% | Aktien |
| New Millennium Group LLC | $1.756 | 5.750 | 0,19% | Aktien |
| IFP Advisors, Inc | $55 | 100 | 0,01% | Aktien |
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Shao-Lee Lin | 21. August 2026 | 6,20% | Erste Einreichung | · | SEC |
| Christopher A. Marlett 2) ×2 Einreichungen | 21. April 2020 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 35 Insider · 18 Führungskräfte · 19 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Shao-Lee Lin | Chief Executive Officer | 12. August 2026 M | 705.995 | 1 | 5 | $-606.596 |
| Usman Azam | CHIEF EXECUTIVE OFFICER | 29. September 2025 A | · | 0 | 0 | $0 |
| Daniel R Passeri | CHIEF EXECUTIVE OFFICER | 21. März 2025 A | 164.578 | 0 | 0 | $0 |
| James M Ahlers | Chief Financial Officer | 30. Juli 2026 A | 25.500 | 0 | 0 | $0 |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | 21. März 2025 A | 14.311 | 0 | 0 | $0 |
| Anish Suri | PRESIDENT AND CSO | 5. Juni 2024 A | 135.638 | 0 | 0 | $0 |
| Michael Vincent Meluzio | VP, Prin. Accounting Officer | 13. August 2026 M | 48.961 | 0 | 3 | $-169.323 |
| Sumita Ray | Chief Legal Compliance Officer | 13. August 2026 M | 118.545 | 0 | 3 | $-265.629 |
| Dominique Christian Borie | Chief Medical Officer | 13. Juli 2026 A | 31.500 | 0 | 0 | $0 |
| Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | 9. April 2026 A | · | 0 | 0 | $0 |
| Lucinda Warren | CHIEF BUSINESS OFFICER | 9. April 2026 A | · | 0 | 0 | $0 |
| Colin Sandercock | SVP, GENERAL COUNSEL | 9. April 2026 A | 17.125 | 0 | 0 | $0 |
| Matteo Levisetti | Chief Medical Officer | 21. März 2025 A | · | 0 | 0 | $0 |
| Patricia Nasshorn | Chief Business Officer | 16. Februar 2023 A | · | 0 | 0 | $0 |
| Kenneth Pienta | Chief Medical Officer | 25. März 2022 A | 2.000 | 0 | 0 | $0 |
| Bethany Mancilla | SVP and Chief Business Officer | 6. März 2019 A | · | 0 | 0 | $0 |
| Ronald D. Seidel III | EVP, Head of R&D | 23. Juli 2018 A | · | 0 | 0 | $0 |
| Rodolfo Chaparro | EVP, Head of Immunology | 23. Juli 2018 A | · | 0 | 0 | $0 |
| Viola Mong Meehan | Direktor | 9. Juli 2026 A | 21.800 | 0 | 0 | $0 |
| Pasha Sarraf | Direktor | 9. Juli 2026 A | 29.195 | 5 | 0 | $99.719 |
| Pamela Garzone | Direktor | 9. Juli 2026 A | 18.900 | 0 | 0 | $0 |
| Daniel A. Camardo | Direktor | 9. Juli 2026 A | 21.800 | 0 | 0 | $0 |
| Patrick Verheyen | Direktor | 2. Januar 2026 A | · | 0 | 0 | $0 |
| Frank Morich | Direktor | 2. Januar 2026 A | 28.000 | 0 | 0 | $0 |
| Peter A Kiener | Direktor | 2. Januar 2026 A | 357 | 0 | 0 | $0 |
| Jill Marie Broadfoot | Direktor | 2. Januar 2026 A | · | 0 | 0 | $0 |
| Frederick W Driscoll | Direktor | 2. Januar 2025 A | · | 0 | 0 | $0 |
| Michael J Fox | Direktor | 5. Juni 2024 A | · | 0 | 0 | $0 |
| Fletcher Aaron G.L. | Direktor | 3. Januar 2023 A | 940.000 | 0 | 0 | $0 |
| Tamar D Howson | Direktor | 3. Januar 2023 A | · | 0 | 0 | $0 |
| Cameron Gray | Direktor | 14. Juni 2022 X | 687.049 | 0 | 0 | $0 |
| Steven L Mcknight | Direktor | 2. Januar 2020 A | · | 0 | 0 | $0 |
| Christopher A Marlett | Direktor | 2. Januar 2020 A | 0 | 0 | 0 | $0 |
| Anthony DiGiandomenico | Direktor | 24. Dezember 2018 P | 30.000 | 0 | 0 | $0 |
| Barry J. Simon | · | 4. Januar 2021 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 3 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
CUE Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 6 Analysten
KAUF
Median-Ziel
$83.00
+224,6%
2 33,3%
Starker Kauf
3 50,0%
Kauf
1 16,7%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
3 Analysten · 2026-10-01Mittelwert-Ziel $88.00 +244,2%
← Unter allen Zielen
Aktueller Preis $25.57
Tief$66.00
Mittelwert$88.00
Hoch$115.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| CUE | $29M | -1.1 | 195.8% | -96.9% | -119.3% | · |
| ALEC | $172M | -1.1 | -79.1% | -679.2% | -280.7% | · |
| WHWK | $114M | -7.3 | -72.5% | -288.3% | -13.4% | · |
| TRDA | $394M | -3.0 | -87.9% | -565.5% | -41.9% | · |
| ELDN | $114M | -2.9 | · | · | -69.4% | · |
| PYXS | $72M | -0.9 | -14.2% | -574.5% | -112.9% | · |
| CHRS | $172M | 1.0 | 59.8% | 398.4% | 185.8% | · |
| NKTX | $131M | -1.3 | · | · | -31.1% | · |
| CNTN | $112M | -2.7 | · | · | -18.0% | · |
| ORGO | $658M | 34.5 | 17.0% | 6.6% | 13.9% | · |
| DTIL | $100M | -1.2 | -50.1% | -133.4% | -72.4% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 14, 2026